Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
Separately, Wall Street Zen downgraded Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Galmed Pharmaceuticals currently has an average rating of “Reduce”.
Check Out Our Latest Research Report on Galmed Pharmaceuticals
Galmed Pharmaceuticals Stock Performance
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- Conference Calls and Individual Investors
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- How to Evaluate a Stock Before Buying
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- Market Cap Calculator: How to Calculate Market Cap
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.